Q4 2025 earnings call recap: evorpacept/CD47 biomarker data, ASPEN-09 expansion, ALX2004 updates, and $150M raise—read now.
ALX Oncology pivots to targeting HER2-positive underperformance in the intent-to-treat gastric cancer population. See why ...
Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains ...
Elon Musk and other tech leaders explore building data centres in space to overcome terrestrial constraints, with launch ...
As AI scaling laws hit the data plateau, executives face a stark choice: hit the scaling wall or remain an innovator. This ...
The Associated Press today announced that it will provide its U.S. elections results to Kalshi, the world’s largest prediction market. AP will provide ...
When the IBM PC was new, I served as the president of the San Francisco PC User Group for three years. That’s how I met PCMag’s editorial team, who brought me on board in 1986. In the years since that ...
Why psychiatry’s diagnostic system may undergo major changes, and what the scientific debates over how mental illnesses should be defined are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results